Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interleukin (IL) 1-beta in small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001
Association between proinflammatory cytokines (TNFa and IL8) and fibrinolytic system in malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 494s Year: 2004
Cytokines in asthma Source: Eur Respir J 2001; 18: 24S-33S Year: 2001
Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection Year: 2006
Targeting TNF-alpha in inflammatory lung diseases Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005
Some of the tumor necrosis factor receptor superfamilies and their concentrations in serum during chemotherapy of lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006
The impact of microRNAs on tuberculosis-induced tumor necrosis factor-α expression in monocytes/macrophages Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009
TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018
Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients Source: Eur Respir J 2007; 30: 701-707 Year: 2007
The levels of tumour necrosis factor-alpha and interleukin-1 in newly diagnosed and multi drug resistant tuberculosis Source: Annual Congress 2004 - Clinical and diagnostic features of tuberculosis Year: 2004
Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002
Tumour necrosis correlates with angiogenesis and is a prognostic factor in malignant mesothelioma Source: Eur Respir J 2002; 20: Suppl. 38, 232s Year: 2002
Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017
Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007
Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene Source: Eur Respir J 2002; 19: 912-918 Year: 2002
Proinflammatory cytokines production in patients with purulent destructive lung diseases Source: Eur Respir J 2001; 18: Suppl. 33, 105s Year: 2001
Decreased levels of CXC angiogenic chemokines (IL-8, ENA-78 and GRO-α) in BALF after interferon gamma-1b treatment in IPF patients Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005
Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis Source: Eur Respir J 2003; 21: 421-428 Year: 2003
Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009
Interleukin-8 and other mediators are related to tumour burden in malignant pleural effusions (MPE) Source: Eur Respir J 2007; 30: Suppl. 51, 103s Year: 2007